- Home
- BCSS vs OVID Comparison
BCSS vs OVID Comparison
Compare BCSS & OVID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
HOLD
HOLD
Current Price
$2.71
Company Overview
Basic Information| Metric | BCSS | OVID |
|---|---|---|
| Founded | 2025 | 2014 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 599.8M | 562.5M |
| IPO Year | 2025 | 2017 |
Fundamental Metrics
Financial Performance| Metric | BCSS | OVID |
|---|---|---|
| Price | $10.28 | $2.71 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $4.60 |
| AVG Volume (30 Days) | 37.4K | ★ 1.5M |
| Earning Date | 01-01-0001 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3.90 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,252,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $19.34 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 1181.27 |
| 52 Week Low | $10.06 | $1.12 |
| 52 Week High | $10.48 | $3.11 |
Technical Indicators
Market Signals| Indicator | BCSS | OVID |
|---|---|---|
| Relative Strength Index (RSI) | 55.64 | 49.99 |
| Support Level | $10.13 | $2.56 |
| Resistance Level | $10.48 | $2.77 |
| Average True Range (ATR) | 0.03 | 0.14 |
| MACD | -0.00 | -0.02 |
| Stochastic Oscillator | 16.67 | 20.97 |
Price Performance
Historical Comparison BCSS
OVID
About BCSS Bain Capital GSS Investment Corp. Class A Ordinary Shares
Bain Capital GSS Investment Corp is a newly organized blank check company.
About OVID Ovid Therapeutics Inc.
Ovid Therapeutics Inc is a biopharmaceutical company that is dedicated to reducing seizures and meaningfully improving the lives of people affected by rare epilepsies and seizure-related neurological disorders. The company has built a differentiated pipeline of medicines with potential first-in-class drug mechanisms of action to treat seizures. This pipeline has produced two epilepsy programs with potential first-in-class mechanisms of action, and one epilepsy program with a potential best-in-class mechanism of action.